{"classes":[{"categories":[{"measurements":[{"comment":"Standard deviation could not be calculated because only one participant was analysed.","groupId":"OG000","spread":"NA","value":"0.993"}]}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"comment":"Standard deviation could not be calculated because only one participant was analysed.","groupId":"OG000","spread":"NA","value":"0.979"}]}],"title":"Cycle 5 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Accumulation Ratio of Cmax was calculated as RAC (Cmax) on Cycle 3 Day 1 divided by RAC (Cmax) on Cycle 1 Day 1, and RAC (Cmax) on Cycle 5 Day 1 divided by RAC (Cmax) on Cycle 1 Day 1.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with relapsed or refractory PTCL and CTCL received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).","id":"OG000","title":"PTCL and CTCL Participants: E7777 9 mcg/kg/Day"}],"paramType":"MEAN","populationDescription":"PK analysis set: group of participants who received at least 1 dose of study drug with at least 1 serum concentration data, and included participants who had taken frequent blood sampling for non-compartment analysis. Overall number of participants analyzed is number of participants with evaluable data at Cycle 1 Day 1 and at Cycles 3 and 5 Day 1","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: 0-240 minutes post-infusion; Cycle 3 and 5 Day 1: 0-120 minutes post-infusion (each Cycle length = 3 weeks)","title":"Rac (Cmax): Accumulation Ratio of Cmax for E7777","type":"SECONDARY","unitOfMeasure":"ratio"}